[go: up one dir, main page]

WO2003042661A3 - Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer - Google Patents

Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer Download PDF

Info

Publication number
WO2003042661A3
WO2003042661A3 PCT/US2002/036810 US0236810W WO03042661A3 WO 2003042661 A3 WO2003042661 A3 WO 2003042661A3 US 0236810 W US0236810 W US 0236810W WO 03042661 A3 WO03042661 A3 WO 03042661A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer
diagnosis
compositions
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/036810
Other languages
English (en)
Other versions
WO2003042661A8 (fr
WO2003042661A2 (fr
Inventor
Daniel Afar
Natasha Aziz
Wendy M Ginsburg
Kurt C Gish
Richard Glynne
Peter A Hevezi
David H Mack
Richard Murray
Susan R Watson
Keith E Wilson
Albert Zlotnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Priority to AU2002357734A priority Critical patent/AU2002357734A1/en
Priority to JP2003544445A priority patent/JP2005525789A/ja
Priority to EP02792272A priority patent/EP1497454A2/fr
Priority to CA002467433A priority patent/CA2467433A1/fr
Publication of WO2003042661A2 publication Critical patent/WO2003042661A2/fr
Publication of WO2003042661A8 publication Critical patent/WO2003042661A8/fr
Anticipated expiration legal-status Critical
Publication of WO2003042661A3 publication Critical patent/WO2003042661A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne des gènes dont l'expression est régulée positivement ou négativement dans certains cancers ou pathologies spécifiques, ou bien dont l'expression est régulée dans les états pathologiques. Sont également décrites des méthodes et des compositions connexes convenant pour le diagnostic, le pronostic et le traitement de ces pathologie ainsi que ces méthodes permettant d'identifier les modulateurs de ces dernières.
PCT/US2002/036810 2001-11-13 2002-11-13 Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer Ceased WO2003042661A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002357734A AU2002357734A1 (en) 2001-11-13 2002-11-13 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
JP2003544445A JP2005525789A (ja) 2001-11-13 2002-11-13 ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
EP02792272A EP1497454A2 (fr) 2001-11-13 2002-11-13 Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
CA002467433A CA2467433A1 (fr) 2001-11-13 2002-11-13 Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer

Applications Claiming Priority (37)

Application Number Priority Date Filing Date Title
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US33246401P 2001-11-21 2001-11-21
US60/332,464 2001-11-21
US33439301P 2001-11-29 2001-11-29
US60/334,393 2001-11-29
US33539401P 2001-12-03 2001-12-03
US60/335,394 2001-12-03
US34037601P 2001-12-14 2001-12-14
US60/340,376 2001-12-14
US34721102P 2002-01-08 2002-01-08
US60/347,211 2002-01-08
US34734902P 2002-01-10 2002-01-10
US60/347,349 2002-01-10
US35525002P 2002-02-08 2002-02-08
US35525702P 2002-02-08 2002-02-08
US60/355,250 2002-02-08
US35671402P 2002-02-13 2002-02-13
US60/356,714 2002-02-13
US35907702P 2002-02-20 2002-02-20
US60/359,077 2002-02-20
US36880902P 2002-03-29 2002-03-29
US60/368,809 2002-03-29
US37011002P 2002-04-04 2002-04-04
US60/370,110 2002-04-04
US37224602P 2002-04-12 2002-04-12
US60/372,246 2002-04-12
US38661402P 2002-06-05 2002-06-05
US60/386,614 2002-06-05
US39683902P 2002-07-16 2002-07-16
US60/396,839 2002-07-16
US39784502P 2002-07-22 2002-07-22
US39777502P 2002-07-22 2002-07-22
US60/397,845 2002-07-22
US60/397,775 2002-07-22
US40945002P 2002-09-09 2002-09-09
US60/409,450 2002-09-09

Publications (3)

Publication Number Publication Date
WO2003042661A2 WO2003042661A2 (fr) 2003-05-22
WO2003042661A8 WO2003042661A8 (fr) 2003-10-16
WO2003042661A3 true WO2003042661A3 (fr) 2004-10-28

Family

ID=32097246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036810 Ceased WO2003042661A2 (fr) 2001-11-13 2002-11-13 Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer

Country Status (1)

Country Link
WO (1) WO2003042661A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840887B2 (en) 2007-09-26 2014-09-23 Genentech, Inc. Antibodies

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
EP1305409B1 (fr) 2000-06-16 2009-03-11 Biogen Idec MA Inc. Elements de regulation renale et leurs procedes d'utilisation
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US7118912B2 (en) * 2002-08-26 2006-10-10 Case Western Reserve University Methods and compositions for categorizing patients
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
DK1401869T3 (da) 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
EP2143437B1 (fr) * 2001-09-18 2013-08-21 Genentech, Inc. Compositions et méthodes pour le diagnostic et le traitement de tumeurs
US20040001840A1 (en) * 2002-03-04 2004-01-01 Young Paul E. Cancer-linked gene as target for chemotherapy
CA2479732A1 (fr) * 2002-03-19 2003-10-02 Curagen Corporation Polypeptides therapeutiques, acides nucleiques codant pour ceux-ci et methodes d'utilisation associees
EP2365004B1 (fr) * 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Marqueurs associés à la membrane d'endothélium tumoral
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
CA2496781A1 (fr) * 2002-08-26 2004-03-04 Case Western Reserve University Methodes de traitement de patients et d'identification de therapeutique
DE60335636D1 (de) * 2002-09-11 2011-02-17 Genentech Inc Zusammensetzungen und verfahren für die tumordiagnose und behandlung
US7521543B2 (en) * 2002-10-23 2009-04-21 Ludwig Institute For Cancer Research A34 and A33-like 3 DNA, proteins, antibodies thereto and methods of treatment using same
DK1585546T3 (da) 2002-12-30 2008-12-08 Biogen Idec Inc KIM- 1- Antagonister og Brug til at Modulere Immunsystem
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
JP2006526986A (ja) * 2003-06-06 2006-11-30 アストラゼネカ・アクチエボラーグ 炎症性大腸炎の診断方法
DK1644406T3 (da) 2003-07-11 2012-11-19 Develogen Ag Anvendelse af DG153-udskilte proteinprodukter til at forebygge og behandle pancreassygdomme og/eller obesitet og/eller metabolisk syndrom
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
CA2761987A1 (fr) 2003-10-07 2005-04-21 Millennium Pharmaceuticals, Inc. Molecules d'acides nucleiques et proteines pour l'identification, l'evaluation, la prevention et le traitement du cancer de l'ovaire
DK1725249T3 (en) 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
WO2005054864A2 (fr) * 2003-11-22 2005-06-16 Bayer Healthcare Ag Diagnostic et traitements therapeutiques des maladies associees a l'element 1 de la sous-famille k du canal potassique (kcnk1)
JP2005230011A (ja) 2004-02-20 2005-09-02 Samsung Electronics Co Ltd 乳ガン関連蛋白質、それをコーディングする遺伝子、及び該蛋白質及び該遺伝子を利用した乳ガンの診断方法
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
JP2005314397A (ja) * 2004-03-31 2005-11-10 Mitsubishi Chemicals Corp 抗コンドロモジュリン−１特異的抗体及びその利用
EP1733743A4 (fr) * 2004-04-09 2007-06-27 Takeda Pharmaceutical Agents de prevention/remedes contre le cancer
KR101200133B1 (ko) 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
AU2005250185A1 (en) * 2004-06-04 2005-12-15 Laboratoires Serono Sa Splice variant of UNC5H2
US20060024677A1 (en) * 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
EP1794314A2 (fr) * 2004-07-23 2007-06-13 Bayer HealthCare AG Agents diagnostiques et therapeutiques pour pathologies associees au recepteur 1 de peptide intestinal vasoactif (vpac1)
WO2006014999A2 (fr) * 2004-07-27 2006-02-09 Five Prime Therapeutics, Inc. Compositions et methodes d'utilisation de modulateurs de nectine 4, de semaphorine 4b, d'igsf9 et de kiaa0152 dans le traitement de maladies
DE102004045705A1 (de) 2004-09-21 2006-04-06 B.R.A.H.M.S Ag Verwendungen der Carbamoylphosphat Synthetase 1(CPS) als humoraler Biomarker für die Diagnose von Tumorerkrankungen und chronisch entzündlichen Darmerkrankungen
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
WO2006053442A1 (fr) * 2004-11-22 2006-05-26 Diagnocure Inc. Cible specifique et sensible (calml3) pour un diagnostic, un pronostic et/ou une therapie adaptee au diagnostic et au savoir-faire du domaine, d'un cancer du poumon
WO2006060533A2 (fr) 2004-12-01 2006-06-08 Genentech, Inc. Conjugues medicament anticorps et procedes correspondants
WO2006090389A2 (fr) * 2005-02-24 2006-08-31 Compugen Ltd. Nouveaux marqueurs diagnostiques, en particulier pour l'imagerie in vivo, et dosage et procedes d'utilisation associes
EP2325305B1 (fr) 2005-02-25 2014-02-12 Oncotherapy Science, Inc. Vaccins à base de peptides pour cancers du poumon exprimant des polypeptides TTK, URLC10 ou KOC1
CN101166542A (zh) 2005-03-02 2008-04-23 比奥根艾迪克Ma公司 用于治疗th2介导的疾病的kim-1抗体
US20080167326A1 (en) * 2005-04-07 2008-07-10 Astrazeneca Ab Method For Assessing the Predisposition and/or Susceptibility to Copd by Analysing Fgf-Bp1
ES2533767T3 (es) 2005-04-15 2015-04-15 Epigenomics Ag Métodos para el análisis de trastornos proliferativos celulares
US20090203639A1 (en) * 2005-04-15 2009-08-13 Oncomethylome Sciences, Inc. Methylation Markers for Diagnoses and Treatment of Cancers
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
EP1897940A4 (fr) 2005-05-02 2009-04-15 Toray Industries Composition et procédé permettant de diagnostiquer un cancer oesophagien et une métastase d'un cancer oesophagien
ATE533781T1 (de) 2005-05-27 2011-12-15 Bbs Bioactive Bone Substitutes Oy Heparin-bindungsstelle enthaltendes knochenmorphogenetisches protein 6 und osteogene vorrichtungen und pharmazeutische produkte, die diese enthalten
DK1957539T3 (da) 2005-12-08 2013-05-06 Medarex Inc Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelse
PL1989231T3 (pl) 2006-03-21 2015-10-30 Genentech Inc Terapia kombinatoryczna z udziałem antagonistów alfa5beta1
WO2007115213A2 (fr) * 2006-03-30 2007-10-11 Epigenomics Ag Méthodes et acides nucléiques pour des analyses de troubles prolifératifs cellulaires
EP2479283B1 (fr) * 2006-04-17 2016-06-22 Epigenomics AG Procédés et acides nucléiques pour la détection de troubles prolifératifs cellulaires colorectaux
WO2008008983A2 (fr) * 2006-07-13 2008-01-17 Epigenomics Ag Procédés et acides nucléiques pour des analyses de problèmes de la prolifération cellulaire
EP1932854A1 (fr) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides s'apparentant à une protéine de membrane associée à un lysosome (LAMP), ligands correspondants et leur utilisation dans le cadre de la détection et de la purification de cellules dendritiques plasmacytoïdes humaines
EP2121738A2 (fr) 2007-02-26 2009-11-25 Oxford Genome Sciences (UK) Limited Protéines
WO2008104803A2 (fr) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Protéines
KR101290892B1 (ko) 2007-07-27 2013-07-31 이매틱스 바이오테크놀로지스 게엠베하 신경 및 뇌 종양에 대한 신규 면역요법
HUE027164T2 (en) 2007-07-27 2016-08-29 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
AU2012244137B2 (en) * 2007-07-27 2015-06-11 Immatics Biotechnologies Gmbh Novel immunotherapy against neuronal and brain tumours
AU2008296927C1 (en) 2007-09-06 2015-08-13 Case Western Reserve University Methods for diagnosing and treating cancers
AU2009207645B2 (en) 2008-01-25 2014-11-13 Aarhus Universitet Selective exosite inhibition of PAPP-A activity against IGFBP-4
CN102014937A (zh) 2008-03-03 2011-04-13 迈阿密大学 基于异基因癌细胞的免疫治疗
EP2119726B2 (fr) * 2008-05-14 2017-11-29 Immatics Biotechnologies GmbH Nouveaux peptides puissants de classe II-MHC dérivés de la survivine et neurocane
WO2009142257A1 (fr) 2008-05-21 2009-11-26 東レ株式会社 Composition et procédé de détermination du cancer de l'œsophage
KR101771714B1 (ko) * 2008-05-30 2017-08-25 제넨테크, 인크. 변이체 ｈｈｉｐ1 단백질 및 방법 및 그의 용도
SG192517A1 (en) 2008-07-15 2013-08-30 Genentech Inc Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
US9290556B2 (en) 2008-09-29 2016-03-22 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
KR101962476B1 (ko) 2009-07-03 2019-03-26 아비펩 피티와이 리미티트 면역성 접합체 및 그 제조방법
WO2011031870A1 (fr) 2009-09-09 2011-03-17 Centrose, Llc Conjugués médicamenteux ciblés à visée extracellulaire
AU2010336029B2 (en) 2009-12-23 2011-10-13 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
MA34277B1 (fr) 2010-04-15 2013-06-01 Spirogen Developments Sarl Pyrrolobenzodiazépines et conjugués de celles-ci
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
TWI524901B (zh) 2010-09-29 2016-03-11 艾澤西公司 與１９１ｐ４ｄ１２蛋白結合之抗體藥物共軛物（ａｄｃ）
ES2544608T3 (es) 2010-11-17 2015-09-02 Genentech, Inc. Conjugados de anticuerpo y de alaninil-maitansinol
EP2699597B1 (fr) 2011-04-21 2016-06-01 Garvan Institute of Medical Research Molécules à domaine variable modifié et procédés de préparation et d'utilisation de celles-ci
KR101992502B1 (ko) 2011-05-12 2019-06-24 제넨테크, 인크. 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법
WO2013045464A1 (fr) * 2011-09-26 2013-04-04 Roche Diagnostics Gmbh Biomarqueurs d'adnc dans du sang total pour l'évaluation du cancer colorectal
SI2750713T1 (sl) 2011-10-14 2016-01-29 Medimmune Limited Pirolobenzodiazepini in njihovi konjugati
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
ES2662808T3 (es) 2012-08-31 2018-04-09 Vasculead Inc. Péptido obtenido de PSF1
BR112015008174B1 (pt) 2012-10-12 2022-12-27 Medimmune Limited Conjugados de pirrolobenzodiazepina-anticorpo, composição farmacêutica compreendendo ditos conjugados e usos dos mesmos para tratar doença proliferativa e cancêr
WO2014057114A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués pyrrolobenzodiazepine-anticorps anti-psma
EP2766048B1 (fr) 2012-10-12 2014-12-10 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
KR101986404B1 (ko) 2012-10-12 2019-06-07 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
HUE039329T2 (hu) 2012-10-12 2018-12-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
DK2906251T3 (da) 2012-10-12 2017-11-20 Adc Therapeutics Sa Pyrrolobenzodiazepin-anti-CD22-antistofkonjugater
CA2894961C (fr) 2012-12-21 2020-09-15 Spirogen Sarl Pyrrolobenzodiazepines et conjugues associes
CN110627797A (zh) 2012-12-21 2019-12-31 麦迪穆有限责任公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
JP6445519B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
WO2015023355A1 (fr) 2013-08-12 2015-02-19 Genentech, Inc. Conjugués anticorps-médicament dimérique 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
MX365742B (es) 2013-10-11 2019-06-12 Oxford Biotherapeutics Ltd Anticuerpos conjugados contra ly75 para el tratamiento del cancer.
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
CN105873614B (zh) 2013-12-16 2020-10-30 基因泰克公司 肽模拟化合物及其抗体-药物缀合物
MX2016007826A (es) 2013-12-16 2017-03-31 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco.
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3191521A2 (fr) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Anticorps et conjugués modifiés génétiquement avec de la cystéine
WO2016040825A1 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
SG11201702079UA (en) 2014-09-17 2017-04-27 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
NZ731782A (en) 2014-11-25 2023-04-28 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CN107206101B (zh) 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (fr) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Conjugués anticorps-protac et procédés d'utilisation
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
CN109476648B (zh) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 司维司群抗体-药物缀合物和使用方法
EP3496763A1 (fr) 2016-08-11 2019-06-19 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
LT3612537T (lt) 2017-04-18 2022-10-10 Medimmune Limited Pirolobenzodiazepino konjugatai
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
WO2019034764A1 (fr) 2017-08-18 2019-02-21 Medimmune Limited Conjugués de pyrrolobenzodiazépine
KR20200055065A (ko) 2017-09-20 2020-05-20 주식회사 피에이치파마 타일란스타틴 유사체
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
IL282441B2 (en) 2018-10-24 2025-07-01 Hoffmann La Roche Conjugated chemical inducers of degradation and methods of use
AU2019392090A1 (en) 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
EP3894427A1 (fr) 2018-12-10 2021-10-20 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
ES2967878T3 (es) 2019-03-15 2024-05-06 Medimmune Ltd Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer
CN112083168A (zh) * 2019-06-14 2020-12-15 复旦大学附属华山医院 多肽段诊断模型及其在预测髓母细胞瘤转移风险中的应用
CN110819714B (zh) * 2019-11-22 2023-01-10 南方医科大学深圳医院 一种抑癌基因及其应用
CN114350640B (zh) * 2019-12-13 2023-09-08 中国科学院天津工业生物技术研究所 一株表达几丁质酶重组菌的构建及高酶活突变体的筛选
CN111298097B (zh) * 2020-03-30 2022-05-06 山东大学齐鲁医院 皮质抑素14在制备自身免疫炎性疾病治疗药物中的应用
CN111748623B (zh) * 2020-06-08 2022-11-04 郑州大学第一附属医院 肝癌患者是否复发的预测标志物及试剂盒
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2022078524A2 (fr) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps
AR128331A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
CN114966062B (zh) * 2022-07-29 2022-09-30 北京大学第三医院（北京大学第三临床医学院） 用于预测抗mda5抗体阳性皮肌炎合并间质性肺病的分子标记物及其应用
EP4637833A2 (fr) 2022-12-23 2025-10-29 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations
AU2024257248A1 (en) 2023-04-17 2025-11-06 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
CN119979588A (zh) * 2024-12-30 2025-05-13 江南大学 一种降低副产物的甾醇c24-还原酶突变体及产7-脱氢胆固醇的酿酒酵母
CN119970996B (zh) * 2025-02-25 2025-09-09 川北医学院 多肽Angio-3在制备治疗肺纤维化药物中的应用
CN120539414B (zh) * 2025-07-31 2025-09-19 安徽医科大学 将胞浆中的fign蛋白作为标记物在制备肺腺癌和/或乳腺癌诊断产品中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM J.Y. ET AL: "Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1512, June 2001 (2001-06-01), pages 335 - 344, XP004245520 *
SATO H. ET AL: "Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins", J. BIOL. CHEM., vol. 274, no. 17, 23 April 1999 (1999-04-23), pages 11455 - 11458, XP002941607 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840887B2 (en) 2007-09-26 2014-09-23 Genentech, Inc. Antibodies
US9284376B2 (en) 2007-09-26 2016-03-15 Genentech, Inc. Antibodies

Also Published As

Publication number Publication date
WO2003042661A8 (fr) 2003-10-16
WO2003042661A2 (fr) 2003-05-22

Similar Documents

Publication Publication Date Title
WO2003042661A8 (fr) Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
WO2004073657A3 (fr) Methode de diagnostic du cancer, composition et methodes de criblage destinees a identifier des modulateurs du cancer
WO2002059377A3 (fr) Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein
WO2003025138A3 (fr) Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer
WO2003003906A3 (fr) Procede de diagnostic du cancer de la vessie, compositions et procedes de criblage de modulateurs du cancer de la vessie
WO2002102235A3 (fr) Procedes de diagnostic du cancer ovarien, compositions et procedes de criblage de modulateurs du cancer ovarien
WO2004048938A3 (fr) Procedes de detection du sarcome des tissus mous, compositions et procedes de criblage des modulateurs du sarcome des tissus mous
WO2004113571A3 (fr) Genes specifiques de la prostate et leur utilisation comme cibles dans le traitement et le diagnostic du cancer de la prostate
WO2002030268A3 (fr) Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
EP2261369A3 (fr) Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
WO2005047534A3 (fr) Procedes et compositions de prediction de reponse de la neoplasie maligne a un traitement
EP2228654A3 (fr) Diagnostic et traitement de l'invasion des cellules cancéreuses
EP1365034A3 (fr) Procédés et compositions pour la prédiction, le diagnostic, le pronostic, la prévention et le traitement de neoplasie maligne
WO2003087831A3 (fr) Proteines impliquees dans le cancer du sein
TNSN05300A1 (en) Treatment with anti-vegf antibodies
DE60028970D1 (de) An her2 bindende peptidverbindungen
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2003079982A3 (fr) Amplification de genes en cas de cancer
WO2001071357A3 (fr) Proteines, genes et leur utilisation pour diagnostiquer et traiter le cancer de la poitrine
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2002067771A3 (fr) Recepteurs de chimiokine et maladies associees
WO2006027693A8 (fr) Genes et arn variants specifiques de tumeur et leurs utilisations comme cibles pour le traitement et le diagnostic du cancer
WO2005051990A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du sein
WO2004003166A3 (fr) Anticorps et leurs applications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 21/2003 UNDER (30) REPLACE "NOT FURNISHED" BY "60/355,250"

Free format text: IN PCT GAZETTE 21/2003 UNDER (30) REPLACE "NOT FURNISHED" BY "60/355,250"

WWE Wipo information: entry into national phase

Ref document number: 2002792272

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2467433

Country of ref document: CA

Ref document number: 2003544445

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002792272

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002792272

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)